Myriad Genetics (MYGN) Stock Forecast & Price Target $3.82 0.00 (0.00%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$3.82 0.00 (0.00%) As of 05/22/2026 05:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Analyst Forecasts Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Myriad Genetics - Analysts' Recommendations and Stock Price Forecast (2026) How MarketBeat Calculates Price Target and Consensus Rating Consensus Rating HoldBased on 6 Analyst RatingsSell1Hold4Buy1 Based on 6 Wall Street analysts who have issued ratings for Myriad Genetics in the last 12 months, the stock has a consensus rating of "Hold." Out of the 6 analysts, 1 has given a sell rating, 4 have given a hold rating, and 1 has given a buy rating for MYGN. Consensus Price Target $6.5070.16% Upside According to the 6 analysts' twelve-month price targets for Myriad Genetics, the average price target is $6.50. The highest price target for MYGN is $8.50, while the lowest price target for MYGN is $5.50. The average price target represents a forecasted upside of 70.16% from the current price of $3.82. MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data. Get the Latest News and Ratings for MYGN and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Myriad Genetics and its competitors. Sign Up View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. MYGN Analyst Ratings Over TimeTypeCurrent Forecast5/25/25 to 5/25/261 Month Ago4/25/25 to 4/25/263 Months Ago2/24/25 to 2/24/261 Year Ago5/25/24 to 5/25/25Strong Buy0 Strong Buy rating(s)0 Strong Buy rating(s)0 Strong Buy rating(s)0 Strong Buy rating(s)Buy1 Buy rating(s)4 Buy rating(s)4 Buy rating(s)4 Buy rating(s)Hold4 Hold rating(s)6 Hold rating(s)6 Hold rating(s)9 Hold rating(s)Sell1 Sell rating(s)1 Sell rating(s)3 Sell rating(s)3 Sell rating(s)Consensus Price Target$6.50$8.94$9.39$14.79Forecasted Upside70.16% Upside86.98% Upside111.94% Upside278.15% UpsideConsensus RatingHoldHoldHoldHold MYGN Analyst Recommendations By MonthAnalyst Ratings Chart DescriptionThe chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.Skip Chart & View Analyst Rating History MYGN Price Targets by MonthAverage Share Price and Price Target by Month Chart DescriptionThe chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table Myriad Genetics Stock vs. The CompetitionTypeMyriad GeneticsMedical CompaniesBroader MarketConsensus Rating Score 2.00 2.30 2.52Consensus RatingHoldHoldModerate BuyPredicted Upside70.16% Upside1,718.94% Upside15.09% UpsideNews Sentiment RatingPositive NewsSee Recent MYGN NewsNeutral NewsPositive News Recent Analyst Forecasts and Stock Ratings All Ratings Strong Buy Buy Hold Sell Rating Show All Upside > 100% Upside 50% - 100% Upside 20% - 50% Upside 10% - 20% Upside 0% - 10% Downside 0% - 10% Downside 10% - 20% Downside 20% - 50% Downside 50% - 100% Downside > 100% Upside/Downside All Actions Upgrades Downgrades Initiates Coverage Raises Target Lowers Target Reiterates Rating Action Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 3 Years 5 Years Time Frame Start Date End Date Most Recent from Each Brokerage All Show Export DateBrokerageAnalystActionRatingPrice TargetReport Date Upside/DownsideDetails5/18/2026 Weiss RatingsNot Rated DowngradeSell (D-) ➝ Sell (E+)5/6/2026 TD Cowen3 of 5 starsKyle BoucherNot RatedLower TargetHold$7.00 ➝ $6.00+44.89%5/6/2026 Wells Fargo & Company3 of 5 starsBrandon Couillard3 of 5 starsLower TargetEqual Weight$6.00 ➝ $5.50+39.42%2/26/2026 Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy rating UpgradeStrong Sell ➝ Hold2/24/2026 UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLu LiSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingLower TargetNeutral$8.00 ➝ $6.00+36.99%11/11/2025 Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDave WeinerSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingLower TargetOverweight$9.00 ➝ $8.50+27.72%5/21/2025 ScotiabankSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSung Ji NamSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingDowngradeSector Outperform ➝ Sector Perform$20.00 ➝ $6.00+34.83%5/8/2025 Wolfe ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDoug SchenkelSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingDowngradeOutperform ➝ Peer Perform5/7/2025 Craig HallumSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBill BonelloSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingSet TargetBuy$18.00+322.44%5/7/2025 The Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingMatthew SykesSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingLower TargetBuy$14.00 ➝ $8.00+72.82% Get the Latest News and Ratings for MYGN and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Myriad Genetics and its competitors with MarketBeat's FREE daily newsletter. 5/7/2025 Raymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingAndrew CooperSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingReiterated RatingOutperform$19.00 ➝ $10.00+108.77%4/9/2025 GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSubbu NambiSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingDowngradeBuy ➝ Neutral3/3/2025 Bank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDerik De BruinSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingLower TargetUnderperform$13.00 ➝ $11.00+2.52%1/16/2025 StephensSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingMason CarricoSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingReiterated RatingEqual Weight$20.00 ➝ $20.00+61.29%12/9/2024 Leerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy rating DowngradeOutperform ➝ Market Perform$30.00 ➝ $21.00+38.80%11/18/2024 Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy rating Lower TargetEqual Weight$32.00 ➝ $21.00+37.70%8/7/2024 JPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating Boost TargetUnderweight$17.00 ➝ $20.00-23.95%6/3/2024 Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy rating Reiterated RatingHold ➝ Underperform$25.00 ➝ $20.00-10.11%Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Monday at 09:07 PM ET. MYGN Forecast - Frequently Asked Questions What is Myriad Genetics' forecast for 2026? According to the research reports of 6 Wall Street equities research analysts, the average twelve-month stock price forecast for Myriad Genetics is $6.50, with a high forecast of $8.50 and a low forecast of $5.50. Should I buy or sell Myriad Genetics stock right now? 6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Myriad Genetics in the last year. There is currently 1 sell rating, 4 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" MYGN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MYGN, but not buy additional shares or sell existing shares. Does Myriad Genetics's stock price have much upside? According to analysts, Myriad Genetics's stock has a predicted upside of 70.16% based on their 12-month stock forecasts. Has Myriad Genetics been upgraded or downgraded by Wall Street analysts recently? Over the previous 90 days, Myriad Genetics's stock had 2 upgrades and 1 downgrade by analysts. What analysts cover Myriad Genetics? Myriad Genetics has been rated by research analysts at TD Cowen, UBS Group, Weiss Ratings, Wells Fargo & Company, and Zacks Research in the past 90 days. Do Wall Street analysts like Myriad Genetics more than its competitors? Analysts like Myriad Genetics less than other "medical" companies. The consensus rating score for Myriad Genetics is 2.00 while the average consensus rating score for "medical" companies is 2.30. Learn more on how MYGN compares to other companies. Stock Forecasts and Research Tools Related Companies ZBIO Stock Forecast LXRX Stock Forecast MNKD Stock Forecast OPK Stock Forecast GERN Stock Forecast IRWD Stock Forecast CBIO Stock Forecast RIGL Stock Forecast XOMA Stock Forecast EBS Stock Forecast Today's Analyst Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top-Rated Stocks Top Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Most-Upgraded Stocks Most-Downgraded Stocks Lowest-Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter Brokerages With Myriad Genetics RecommendationsWeiss RatingsTD CowenWells Fargo & CompanyZacks ResearchUBS GroupPiper Sandler This page (NASDAQ:MYGN) was last updated on 5/25/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | SponsoredSpaceX will mint billionaires. You won't be one of them.By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billio...Behind the Markets | SponsoredSatellite Images Spot Potential $10 Trillion Discovery'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...Altimetry | SponsoredHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Myriad Genetics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Myriad Genetics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
